Drug Screening Market size was valued at USD 9.13 Bn. in 2023 and the total Drug Screening revenue is expected to grow at a CAGR of 15.97% from 2024 to 2030, reaching nearly USD 25.78 Bn.Drug Screening Market Overview:
The technique of detecting illegal and prescribed medications in blood, urine, and other biological samples is known as drug screening. A drug screening method is also known as the analysis and detection of performance-enhancing substances (such as steroids and HGH) used by professional athletes to enhance stamina and performance during competition. Heroin, cannabis, cocaine, methamphetamines, methadone, and amphetamine are some of the most often used illicit substances. Many countries are concerned about the rising prevalence of such drug usage throughout the globe. According to the National Institute on Drug Abuse (NIDA), an estimated 22.6 million people in the United States used illegal drugs in 2010, accounting for an estimated 8.9% of the total population. The increasing consumption of alcohol among youngsters and the older population, overuse of prescribed prescription medicines, and increased use of opioid painkillers and illegal drugs are the primary driving factors for the market growth. Likewise, increased illegal drug usage and rising crime rates related to drug addiction are expected to drive the demand for drug screening. Increased competitiveness among manufacturers, including organizations working on new goods in a broader variety of categories, is acquiring a larger part of the market. Meanwhile, technological advancements are expected to drive the global drug screening market throughout the forecast period. In addition, the COVID-19 outbreak resulted in a rise in drug and alcohol abuse, as mental health issues were on the upsurge. Similarly, narcotics traffickers have recovered from initial difficulties caused by the pandemic lockdown, because of advances in technology and virtual currency transactions that operate outside of the regular banking system, providing more anonymity. Because of these factors, the demand for drug screening products and services is expected to increase. Increased knowledge about the dangers of driving while drunk, as well as alcohol and drug restrictions in businesses and government organizations, are expected to restrict the global drug screening market growth. However, alcohol restrictions in many Islamic nations, as well as a lack of infrastructure in developing economies, are expected to constrain the global drug screening market's growth.To know about the Research Methodology :- Request Free Sample ReportDrug Screening Market Dynamics:
High demand for Pre-employment Drug Screenings across the industries Pre-employment drug testing assists organizations in mitigating risks, as hiring a drug-addicted individual is dangerous and costly. Absenteeism, workers' compensation claims, and potential legal ramifications generated by a single rogue employee can bankrupt a company. A pre-employment drug test is done to detect whether a prospective employee takes illegal drugs or abuses prescription medicine. It may also be used for personnel returning to work following an accident or absence, in which case it is known as a pre-placement drug test. Employers frequently ask job candidates to take a pre-employment drug test, and a job offer may be reliant on the applicant's ability to pass. Employee drug testing is rapidly performed across many industries, but it is especially important in areas where employee attention is critical to safety and security. Companies frequently conduct drug tests on personnel who operate heavy machinery, drive automobiles on the job, or work with dangerous products. Organizations that influence others' health and safety owe it to the community, their shareholders, and the rest of their staff to promote a drug-free workplace. Other businesses utilize drug testing to increase productivity and reduce absenteeism. Workplace testing is fraught with controversy in these settings. Critics of drug testing say that drug users outside of the office are a private concern that has no bearing on job performance. They argue that the tests are intrusive, unneeded, and ethically wrong, especially when used to establish job status, because of the high likelihood of false positives and findings that represent usage from hours, days, or even weeks before the test is conducted. Employee drug testing may make sense for certain organizations, but in all circumstances, tests used must reflect a careful consideration of the costs and benefits. As a result, the demand for drug screening is rapidly increasing and driving the drug screening market during the forecast period. Rising drug and alcohol consumption among Millennials Drug and alcohol addiction are on the upsurge all around the globe. According to the World Drug Report 2021, an estimated 275 million persons globally aged 15-64, or one in every 18 in that age group, took drugs at least once in the preceding year in 2019 (range: 175 million to 374 million). Drug consumption problems were affect 36.3 million individuals, or over 13% of the global population, in 2019. In the same year, drug use killed about 500,000 individuals, while drug use disorders resulted in the loss of 18 million years of a healthy life, primarily owing to opioids. Similar increases in alcohol intake have been seen, with the result being an increase in the prevalence of impaired driving. The increased consumption of illicit substances and alcohol would drive the production of drug-screening goods and services on the road, ultimately driving the drug screening market growth during the forecast period.Prohibition on workplace drug testing Some countries, including Canada, Colombia, Argentina, Chile, and South Africa, regard workplace drug and alcohol testing to be a violation of employee privacy. In France, for example, pre-employment drug testing is only undertaken when physicians prescribe it. Drug and alcohol testing in the workplace is illegal in Poland and the Czech Republic. Eastern Canadian case rules allow drug and alcohol testing only when occupational activities are fundamentally risky or when drug and alcohol testing is confined to a few unique instances. Such bans in certain nations may restrict the adoption of drug and alcohol testing in these industries, hence restraining drug screening market growth. Fingerprint-based drug testing offers lucrative opportunities Fingerprint-based drug testing is a new concept that has gained popularity as a result of the COVID-19 outbreak. The coronavirus has made drug testing in hospitals, labs, and other institutions complicated owing to the danger of viral transmission. Although fingerprint-based drug screening can help prevent the spread of COVID, it is non-invasive, portable, less time-consuming, and sanitary allows for social distancing, is user-friendly, and does not need any special preparation for sample collection and processing. This test is simple to administer whenever and wherever it is needed, providing flexible and effective workplace drug testing. To identify drugs and drug metabolites, the test examines microscopic amounts of perspiration in the fingerprint. This test is utilized in the workplace, criminal justice, law enforcement, and drug treatment programs. To identify drugs and drug metabolites, the test examines microscopic amounts of perspiration in the fingerprint. If extensively used, this test is expected to replace urine, hair, and blood-based drug testing. This is a substantial opportunity for drug screening market participants to gain in the drug screening business.Drug Screening Market Segment Analysis:
Based on the Sample Type, the Urine Samples segment held the largest share of about 42% and dominated the Drug Screening market in 2023. This segment is further expected to grow at a CAGR of about 11.8% during the forecast period and maintain its dominance at the end of the forecast period. The fact that urine samples are the most often utilized sample type to identify the presence of illegal drugs is attributed to the segment's growth. Drug presence may be easily detected and is less painful than a blood sample. the Urine is the most widely used matrix for drug testing, and it is a simple and direct sample to analyze. Urine testing is highly accurate and takes little time. Urine screening may detect amphetamines or methamphetamines, barbiturates, benzodiazepines, cocaine, marijuana, MDA-analogues (MDA or MDMA), opiates (codeine, morphine, 6-acetylmorphine [indicative of heroin use], hydromorphone, hydrocodone, oxymorphone, and oxycodone), nicotine, or alcohol. the Urine testing has a shorter window of detection when compared to other types, such as the relatively more expensive hair drug test. In urine testing, illicit drugs can be detected for five to ten days, but hair drug tests can identify drug or alcohol usage for up to 90 days. However, adulteration in urine samples is becoming increasingly widespread, resulting in a false-negative test result, which can have a detrimental influence on market growth. If false-positive immunoassay findings are not validated by secondary analysis, such as gas chromatography-mass spectrometry, they might have major medical or societal ramifications.The blood samples segment is expected to grow at a significant CAGR throughout the forecast period. Blood testing is extremely accurate, but it is also expensive and intrusive. It does, however, have a shorter detection time (minutes to hours). A blood drug test detects the presence of drugs or alcohol in the blood at the moment of sample collection. Amphetamines, barbiturates, phencyclidine (PCP), cocaine, marijuana, methamphetamines, opiates, nicotine, and alcohol may be detected with this test. Because blood drug tests have a very small detection window, they are utilized when the person is suspected of being under the influence of drugs or alcohol at the time of the test. While drugs can be discovered in the urine for many days and in hair for several months, the duration in the blood is generally minutes to hours. As a result, blood testing only offers a glimpse of current users. It is frequently used at accident scenes to determine whether anyone involved was under the influence of drugs or alcohol.Regional Insights:
The North American market held the largest market share of about 38.8% and dominated the Drug Screening Market in 2023. This region is further expected to maintain its dominance at the end of the forecast period. The North American market's dominance is attributed to factors such as growing illicit drug consumption, the allocation of government funding to combat drug abuse, laws supporting drug screening, the rising burden of accidents caused by alcohol impairment, and the presence of key players in the region, all of which are driving the growth of the drug screening market in this region. One of the key drivers of regional growth is the prominent players undertaking broad expansion strategies and stringent rules for workplace testing. Likewise, attractive reimbursement conditions and wide adoption of highly technological solutions in the region drive market growth. According to the Substance Abuse and Mental Health Services Administration's 2020 National Survey on Drug Use and Health, more than 59 million Americans aged 12 and older reported taking illegal drugs in the previous year. Employees who abuse drugs are more likely to leave work, arrive late, change jobs often, be engaged in workplace incidents in which others are injured, and submit more workers' compensation claims, according to the National Institute on Drug Abuse. Pre-employment drug testing and routine employee screens are crucial for workplace safety and can assist organizations in combating high attrition rates, increasing employee morale, and saving money. Pre-employment and routine drug screening for candidates and workers is noticeable in specific sectors. As a result, these factors are driving the drug screening market growth in the region. Transportation businesses that recruit truck drivers, taxi drivers, and bus drivers, for example, have rapidly incorporated drug testing as a routine component of their hiring processes. The transportation business is also subject to stringent laws that require pre-employment DOT drug tests and random driver tests. Other industries, such as construction and healthcare, also consider pre-employment drug screenings due to possible safety risks. As a result, the need for Drug Screening is rapidly increasing across a wide range of industries. The Drug Screening market in the United States is expected to increase significantly during the forecast period. The country's need for drug testing is significantly growing due to factors such as increased demand from military sectors for testing their officers, athletes, and sportsmen, among others. Additionally, severe federal government rules encourage market growth in the United States. The United States Department of Transportation (DOT), which is in charge of assisting in the safety of air travel, commercial motor vehicles, railroad transportation, mass transit, hazardous materials, and maritime business, began requiring drug testing of federally regulated, safety-sensitive employees working in these areas. Federal drug testing cleared the path for private-sector firms to launch workplace drug testing programs to screen applicants and workers. The Asia-Pacific market is expected to grow at a CAGR of 12.5% during the forecast period as a result of the growing demand for substance abuse screening from emerging economies such as China and India. The growing frequency of substance misuse problems, drug-related crimes, and deadly traffic accidents in these countries has increased the demand for drug testing. In addition, a rapidly increasing number of drug addicts, the advancement of advanced drug and alcohol screening devices, increased awareness of the importance of alcohol and drug screening, and private institutes toward the drug detection system are expected to play a significant role in the growth of the Asia Pacific drug screening market. According to the United Nations Drug Report, India is the largest user of heroin in South Asia. Recreational substances such as cocaine and cannabis are becoming increasingly popular among those aged 25 to 34. Employers must utilize the information to ensure that there is no substance misuse or drunkenness in the workplace. In this country, drug testing job candidates is quite crucial. As a result, the need for drug screening or testing is increasing. However, the absence of specific legislation governing occupational drug testing is expected to be a key constraint to regional drug screening market growth.Drug Screening Market Scope: Inquire before buying
Drug Screening Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: USD 9.13 Bn. Forecast Period 2024 to 2030 CAGR: 15.97% Market Size in 2030: USD 25.78 Bn. Segments Covered: by Product & Services Drug Screening Product Analytical Instruments Rapid Testing Devices Oral Fluid Testing Devices Consumables Drug Screening Service by Sample Type Urine Samples Blood Samples Oral Fluid Samples Hair Samples Other Samples by Drug Type Alcohol Cannabis/Marijuana Cocaine Opioids Amphetamine & Methamphetamine LSD Others by End-User Drug Testing Laboratories Workplaces Hospitals Others Drug Screening Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key Players are:
1. LabCorp (US) 2. Quest Diagnostics (US) 3. Abbott Laboratories (US) 4. Thermo Fisher Scientific, Inc. (US) 5. Alfa Scientific Designs, Inc. (US) 6. OraSure Technologies, Inc. (US) 7. MPD Inc. (US) 8. LifeLoc Technologies (US) 9. Premier Biotech, Inc. (US) 10.Omega Laboratories, Inc. (US) 11.Psychemedics (US) 12.Clinical Reference Laboratory (US) 13.American Bio Medica Corporation (US) 14.ACM Global Laboratories (US) 15.Care Health America Corp (US) 16.Sciteck, Inc. (US) 17.Synens (France) 18.Intoximeters (US) 19.AccuSource (US) 20.Cordant Health Solutions (US) 21.Millennium Health (US) 22.Siemens Healthineers (Germany) 23.Drägerwerk (Germany) 24.Synens SAS (France) 25.Roche (Switzerland) Shimadzu (Japan) FAQs: 1. What are the growth drivers for the Drug Screening market? Ans. The increasing consumption of alcohol among youngsters and the older population, overuse of prescribed prescription medicines, and increased use of opioid painkillers and illegal drugs, increased illegal drug usage and rising crime rates related to drug addiction, Increased competitiveness among manufacturers are expected to be the major driver for the Drug Screening market. 2. What is the major restraint for the Drug Screening market growth? Ans. The Prohibition on workplace drug testing, alcohol restrictions in many Islamic nations, as well as a lack of infrastructure in developing economies, are expected to be the major restraining factor for the Drug Screening market growth. 3. Which region is expected to lead the global Drug Screening market during the forecast period? Ans. The North American market is expected to lead the global Drug Screening market during the forecast period due to the growing illicit drug consumption, the allocation of government funding to combat drug abuse, laws supporting drug screening, the rising burden of accidents caused by alcohol impairment, and the presence of key players in the region. 4. What is the projected market size & growth rate of the Drug Screening Market? Ans. The Drug Screening Market size was valued at USD 9.13 Bn. in 2023 and the total Drug Screening revenue is expected to grow at a CAGR of 15.97% from 2024 to 2030, reaching nearly USD 25.78 Bn. 5. What segments are covered in the Drug Screening Market report? Ans. The segments covered in the drug screening market are Product & Services, Sample Type, Drug Type, End User, and Region.
1. Global Drug Screening Market: Research Methodology 2. Global Drug Screening Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Drug Screening Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Drug Screening Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Drug Screening Market Segmentation 4.1 Global Drug Screening Market, by Product & Services (2023-2030) • Drug Screening Product • Analytical Instruments • Rapid Testing Devices • Oral Fluid Testing Devices • Consumables • Drug Screening Service 4.2 Global Drug Screening Market, by Sample Type (2023-2030) • Urine Samples • Blood Samples • Oral Fluid Samples • Hair Samples • Other Samples 4.3 Global Drug Screening Market, by Drug Type (2023-2030) • Alcohol • Cannabis/Marijuana • Cocaine • Opioids • Amphetamine & Methamphetamine • LSD • Others 4.4 Global Drug Screening Market, by End-user (2023-2030) • Drug Testing Laboratories • Workplaces • Hospitals • Others 5. North America Drug Screening Market(2023-2030) 5.1 North America Drug Screening Market, by Product & Services (2023-2030) • Drug Screening Product • Analytical Instruments • Rapid Testing Devices • Oral Fluid Testing Devices • Consumables • Drug Screening Service 5.2 North America Drug Screening Market, by Sample Type (2023-2030) • Urine Samples • Blood Samples • Oral Fluid Samples • Hair Samples • Other Samples 5.3 North America Drug Screening Market, by Drug Type (2023-2030) • Alcohol • Cannabis/Marijuana • Cocaine • Opioids • Amphetamine & Methamphetamine • LSD • Others 5.4 North America Drug Screening Market, by End-user (2023-2030) • Drug Testing Laboratories • Workplaces • Hospitals • Others 5.5 North America Drug Screening Market, by Country (2023-2030) • United States • Canada • Mexico 6. Europe Drug Screening Market (2023-2030) 6.1. European Drug Screening Market, by Product & Services (2023-2030) 6.2. European Drug Screening Market, by Sample Type (2023-2030) 6.3. European Drug Screening Market, by Drug Type (2023-2030) 6.4. European Drug Screening Market, by End-user (2023-2030) 6.5. European Drug Screening Market, by Country (2023-2030) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Drug Screening Market (2023-2030) 7.1. Asia Pacific Drug Screening Market, by Product & Services (2023-2030) 7.2. Asia Pacific Drug Screening Market, by Sample Type (2023-2030) 7.3. Asia Pacific Drug Screening Market, by Drug Type (2023-2030) 7.4. Asia Pacific Drug Screening Market, by End-user (2023-2030) 7.5. Asia Pacific Drug Screening Market, by Country (2023-2030) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Drug Screening Market (2023-2030) 8.1 Middle East and Africa Drug Screening Market, by Product & Services (2023-2030) 8.2. Middle East and Africa Drug Screening Market, by Sample Type (2023-2030) 8.3. Middle East and Africa Drug Screening Market, by Drug Type (2023-2030) 8.4. Middle East and Africa Drug Screening Market, by End-user (2023-2030) 8.5. Middle East and Africa Drug Screening Market, by Country (2023-2030) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Drug Screening Market (2023-2030) 9.1. South America Drug Screening Market, by Product & Services (2023-2030) 9.2. South America Drug Screening Market, by Sample Type (2023-2030) 9.3. South America Drug Screening Market, by Drug Type (2023-2030) 9.4. South America Drug Screening Market, by End-user (2023-2030) 9.5. South America Drug Screening Market, by Country (2023-2030) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 LabCorp (US) 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Quest Diagnostics (US) 10.3 Abbott Laboratories (US) 10.4 Thermo Fisher Scientific, Inc. (US) 10.5 Alfa Scientific Designs, Inc. (US) 10.6 OraSure Technologies, Inc. (US) 10.7 Siemens Healthineers (Germany) 10.8 Roche (Switzerland) 10.9 MPD Inc. (US) 10.10 Shimadzu (Japan) 10.11 LifeLoc Technologies (US) 10.12 Drägerwerk (Germany) 10.13 Premier Biotech, Inc. (US) 10.14 Omega Laboratories, Inc. (US) 10.15 Psychemedics (US) 10.16 Clinical Reference Laboratory (US) 10.17 American Bio Medica Corporation (US) 10.18 ACM Global Laboratories (US) 10.19 Care Health America Corp (US) 10.20 Sciteck, Inc. (US) 10.21 Synens (France) 10.22 Intoximeters (US) 10.23 AccuSource (US) 10.24 Cordant Health Solutions (US) 10.25 Millennium Health (US)